Login to Your Account

Financings Roundup

Jounce Gets $47M Series A, Seeks to Jolt Cancer Therapy

By Marie Powers
Staff Writer

Thursday, February 14, 2013

Third Rock Ventures LLC plumbed its considerable network and assembled a team of prestigious cancer biologists and immunotherapy experts to form Jounce Therapeutics Inc., which launched Thursday with a $47 million Series A financing.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription